Paclitaxel liposomal

Drug Profile

Paclitaxel liposomal

Alternative Names: EndoTAG-1; MBT-0206; SB 05

Latest Information Update: 27 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at San Francisco
  • Developer Jules Bordet Institute; MediGene AG; SynCore Biotechnology
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Pancreatic cancer

Highest Development Phases

  • Phase III Breast cancer
  • No development reported Colorectal cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 19 Apr 2017 SynCore Biotechnology plans a phase III trial for Pancreatic cancer (Late-stage disease, Second-line therapy or greater, Combination therapy, Metastatic disease) (NCT03126435)
  • 01 Nov 2016 Phase-III clinical trials in Breast cancer (Metastatic disease, First-line therapy, Combination therapy) in Taiwan (IV) (NCT03002103)
  • 28 Mar 2016 Syncore Biotechnology acquires ENDOTAG® technology from Medigene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top